Issued Patents All Time
Showing 25 most recent of 48 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12331099 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Kenneth S. Graham, Kelly Frye | 2025-06-17 |
| 12077593 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies | Kenneth S. Graham, Douglas Kamen, Scott Walsh | 2024-09-03 |
| 12070502 | Process for reducing subvisible particles in a pharmaceutical formulation | Hanne BAK, John Mattila, Ning Li, Xiaolin Tang, Chen Li +1 more | 2024-08-27 |
| 11926670 | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies | Xiaolin Tang | 2024-03-12 |
| 11918785 | Devices and methods for overfilling drug containers | Douglas Kamen, Kenneth S. Graham | 2024-03-05 |
| 11806398 | Citrate buffered VEGF antagonist formulations | Kelly Frye, Susan KAUTZ | 2023-11-07 |
| 11732024 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Kenneth S. Graham, Kelly Frye | 2023-08-22 |
| 11673967 | Stabilized formulations containing anti-PCSK9 antibodies | Scott Walsh | 2023-06-13 |
| 11577025 | Devices and methods for overfilling drug containers | Douglas Kamen, Kenneth S. Graham | 2023-02-14 |
| 11098127 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies | Kenneth S. Graham, Douglas Kamen, Scott Walsh | 2021-08-24 |
| 11084865 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Kenneth S. Graham, Kelly Frye | 2021-08-10 |
| 11071780 | Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab | Robert L. Vitti, Kristine A. Erickson, Karen Chu, Stanley Wiegand, Jingtai Cao +3 more | 2021-07-27 |
| 11066458 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Kenneth S. Graham, Kelly Frye | 2021-07-20 |
| 11059896 | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies | Xiaolin Tang | 2021-07-13 |
| 10857231 | Formulations of VEG antagonist fusion proteins and method of manufacturing them | Kelly Frye, Susan KAUTZ | 2020-12-08 |
| 10752701 | Stabilized formulations containing anti-PCSK9 antibodies | Scott Walsh | 2020-08-25 |
| 10472425 | Stabilized formulations containing anti-PCSK9 antibodies | Scott Walsh | 2019-11-12 |
| 10464992 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Kenneth S. Graham, Kelly Frye | 2019-11-05 |
| 10435473 | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies | Xiaolin Tang | 2019-10-08 |
| 10406226 | Method of manufacturing VEGF antagonist fusion proteins | Kelly Frye, Susan KAUTZ | 2019-09-10 |
| 10400025 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Kenneth S. Graham, Kelly Frye | 2019-09-03 |
| 10342876 | Process for reducing subvisible particles in a pharmaceutical formulation | Hanne BAK, John Mattila, Ning Li, Xiaolin Tang, Chen Li +1 more | 2019-07-09 |
| 10072086 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies | Kenneth S. Graham, Douglas Kamen, Scott Walsh | 2018-09-11 |
| 9914763 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Kenneth S. Graham, Kelly Frye | 2018-03-13 |
| 9675692 | Stabilized formulations containing anti-DLL4 antibodies | Scott Walsh | 2017-06-13 |